fign Antibody

What is FIGN/Fidgetin and why is it important in cellular research?

FIGN (Fidgetin) is an ATP-dependent microtubule severing protein that belongs to the AAA ATPase protein family. It functions by severing microtubules along their length and depolymerizing their ends, primarily targeting the minus-end of microtubules . This activity can suppress microtubule growth from and attachment to centrosomes, promoting rapid reorganization of cellular microtubule arrays. Fidgetin's importance in cellular research stems from its critical role in microtubule dynamics, which affects numerous cellular processes including cell division, intracellular transport, and neuronal development. In neurons specifically, Fidgetin preferentially targets labile microtubules in axons, making it a key regulator of axonal growth and regeneration . Understanding Fidgetin's function provides insights into cytoskeletal regulation mechanisms and offers potential therapeutic targets for conditions involving neuronal injury or dysfunction.

What are the most common applications for FIGN antibodies in research?

FIGN antibodies are utilized across various experimental applications in research settings. The most common applications include:

• Western Blotting (WB): Used to detect and quantify FIGN protein expression in cell or tissue lysates, verifying protein size (approximately 82 kDa) and expression levels .

• Immunohistochemistry (IHC): Applied to visualize the distribution and localization of FIGN in tissue sections, particularly in neuronal tissues and organs such as liver and kidney .

• Immunofluorescence (IF): Employed to study the subcellular localization of FIGN and its colocalization with other proteins, especially in relation to microtubule structures .

• ELISA: Used for quantitative detection of FIGN protein in various sample types .

These techniques collectively enable researchers to investigate FIGN expression patterns, subcellular localization, protein-protein interactions, and functional roles in different cellular contexts, particularly in neuronal systems where FIGN plays significant roles in axonal development and regeneration.

How should researchers select the appropriate FIGN antibody for their specific experimental needs?

When selecting a FIGN antibody for research applications, researchers should consider several key factors to ensure optimal experimental outcomes:

• Application compatibility: Verify that the antibody has been validated for your intended application (WB, IHC, IF, or ELISA). For example, some antibodies may perform well in Western blot but poorly in immunohistochemistry .

• Species reactivity: Confirm that the antibody recognizes FIGN in your species of interest. Available antibodies show reactivity with human, mouse, and other species, but cross-reactivity varies between products .

• Epitope location: Consider whether you need an antibody that targets a specific region of FIGN (e.g., C-terminal domain or N-terminal region). This can be important if studying specific isoforms or truncated forms of the protein .

• Validation data: Review the manufacturer's validation data, including images of Western blots, IHC staining patterns, and positive/negative controls .

• Citation record: Check whether the antibody has been successfully used in published research, which provides additional confidence in its performance .

• Conjugation needs: Determine if you require an unconjugated antibody or one conjugated to a specific tag (biotin, FITC, etc.) based on your detection method .

By carefully evaluating these factors, researchers can select the most appropriate FIGN antibody that will yield reliable and reproducible results for their specific experimental requirements.

What tissue types and sample preparations are optimal for FIGN antibody detection?

FIGN antibodies have been successfully used to detect the protein across various tissue types and sample preparations:

• Tissue types: FIGN is widely expressed in many tissues, making it detectable in various human and animal samples. Published data shows successful detection in:

  • Liver tissue (using IHC with paraffin-embedded sections)

  • Kidney tissue (using IHC with paraffin-embedded sections)

  • Neuronal tissues (particularly relevant for axonal studies)

  • Cell lines: HeLa, HEK-293T (human cell lines) and various neuronal cultures

• Sample preparation protocols:

  • For Western blotting: Cell or tissue lysates prepared with standard lysis buffers are suitable. Successful detection has been demonstrated in HeLa cell lysate, pig kidney lysate, and HEK-293T cell lysate .

  • For IHC: Formalin-fixed, paraffin-embedded (FFPE) tissue sections have shown good results with FIGN antibodies. Typically, antibody concentrations of approximately 20 μg/ml have been effective for DAB staining protocols .

  • For neuronal studies: Both primary neuronal cultures and tissue sections from spinal cord or peripheral nerves can be used to study FIGN's role in axonal dynamics .

• Antigen retrieval: For FFPE tissues, appropriate antigen retrieval methods may be necessary to expose epitopes masked during fixation.

Researchers should optimize antibody concentration, incubation conditions, and detection methods based on their specific sample type and experimental goals to achieve optimal signal-to-noise ratios in their FIGN detection assays.

How does FIGN interact with EB3 to regulate microtubule dynamics, and what are the implications for axonal growth?

FIGN (Fidgetin) exhibits a sophisticated interaction with the microtubule end binding protein EB3 to selectively regulate dynamic microtubules in neurons. This interaction has profound implications for axonal growth and regeneration:

The molecular mechanism involves:

• FIGN preferentially interacts with EB3, which localizes to the growing plus-ends of microtubules, particularly those enriched with tyrosinated tubulin (Tyr-MTs) .

• Through this interaction, FIGN gains access to labile microtubules, which represent the dynamic population of microtubules in axons .

• When FIGN is present, it severs these labile microtubules, effectively limiting their growth and stability .

The functional consequences of this interaction include:

• Deletion of FIGN markedly increases the expression of tyrosinated microtubules and EB3 .

• Without FIGN, there is increased accumulation of EB3 at the ends of neurites, promoting microtubule growth .

• The labile portion of microtubules becomes elongated when FIGN is deleted, resulting in increased axon length and enhanced branching .

Research has demonstrated that manipulating this FIGN-EB3 interaction has therapeutic potential. Specifically:

• FIGN knockdown in cultured dorsal root ganglion neurons increased axon length and promoted axon regeneration after injury .

• These effects were attributed to the augmentation of labile microtubules in the absence of FIGN's severing activity .

This mechanistic understanding explains how FIGN preferentially targets dynamic microtubules and suggests that inhibiting FIGN could be a novel approach to enhance axonal regeneration after spinal cord or peripheral nerve injuries.

What are the challenges in studying FIGN's microtubule severing activity, and how do they differ from other severing proteins like katanin and spastin?

Studying FIGN's microtubule severing activity presents unique challenges compared to other severing proteins, particularly in experimental design and functional interpretation:

• Distinctive severing patterns:

  • Unlike katanin and spastin, whose overexpression leads to visible short microtubule fragments, FIGN overexpression does not produce such obvious fragments .

  • This subtle phenotype makes direct visualization and quantification of FIGN's severing activity more challenging, requiring more sensitive detection methods.

• Target specificity differences:

  • FIGN preferentially targets the labile domain of axonal microtubules, which is opposite to the preference of katanin and spastin .

  • This selectivity requires specialized approaches to distinguish between stable and labile microtubule populations, such as using antibodies against post-translationally modified tubulins (e.g., tyrosinated vs. acetylated tubulin).

• Functional readouts:

  • The effects of FIGN manipulation manifest as changes in microtubule stability rather than dramatic fragmentation.

  • Researchers must use indirect measures such as monitoring changes in tyrosinated microtubule levels, neurite length, or branching patterns to assess FIGN activity .

• Experimental approaches:

  • Knockdown/knockout studies have been more informative than overexpression for FIGN, as they reveal its endogenous function through the resulting enhanced microtubule growth and stability .

  • Time-lapse imaging of microtubule dynamics in living cells becomes particularly important to capture the subtle effects of FIGN on microtubule growth rates and catastrophe frequencies.

• Context-dependent activity:

  • FIGN's activity appears to be highly regulated by its interactions with other proteins like EB3 .

  • Studying FIGN in isolation may not fully recapitulate its native function, necessitating more complex experimental systems that maintain these interactions.

Understanding these distinctive features of FIGN is crucial for designing appropriate experimental approaches that can accurately characterize its unique role in microtubule regulation compared to other severing proteins.

What are the most effective approaches for manipulating FIGN expression in neuronal models to study axonal regeneration?

Several effective approaches have been developed for manipulating FIGN expression in neuronal models, each with specific advantages for studying axonal regeneration:

• RNA interference techniques:

  • Small interfering RNA (siRNA) has been successfully used to deplete FIGN in astrocytes, resulting in substantially increased tyrosinated microtubules .

  • This approach offers relatively rapid knockdown but may have transient effects and variable efficiency.

• Viral vector delivery systems:

  • Adeno-associated virus (AAV) serotype 9 carrying U6-shFign-GFP has been effectively employed for in vivo knockdown of FIGN .

  • Implementation protocol: Typically involves injection of 2.7 μL virus (titer: 5 × 10^12 TU/mL) at multiple sites and depths within the spinal cord region of interest .

  • The inclusion of GFP marker allows for visualization of transduced cells.

  • This approach provides longer-term expression compared to transient transfection methods.

• Lentiviral overexpression:

  • LV5-Fign has been used to overexpress FIGN in cultured neurons with a multiplicity of infection of 40 TU/cell .

  • This approach is valuable for gain-of-function studies to complement the knockdown experiments.

  • Protocol typically involves applying virus to 1 × 10^5 cells in 24-well plates, with medium replacement after 18 hours of incubation .

• Combined approaches:

  • Sequential manipulation of FIGN and its interaction partners (e.g., EB3) using siRNA followed by viral overexpression has proven informative for dissecting mechanistic relationships .

  • This combined approach allows researchers to establish epistatic relationships between different factors in the microtubule regulation pathway.

• In vivo applications:

  • For spinal cord injury models, pre-injury viral delivery (typically 2 weeks before modeling) has been successful .

  • Multi-site, multi-depth injections ensure adequate coverage of the injury area.

These approaches have revealed that FIGN depletion leads to increased axon length and enhanced regeneration after injury through augmentation of labile microtubules, suggesting that FIGN inhibition represents a promising therapeutic strategy for promoting axonal regeneration after spinal cord or peripheral nerve injuries.

How can researchers quantitatively assess the effects of FIGN manipulation on microtubule dynamics?

Quantitative assessment of FIGN manipulation effects on microtubule dynamics requires sophisticated methodological approaches that capture both static and dynamic parameters of the microtubule cytoskeleton:

• Post-translational modification analysis:

  • Quantification of tyrosinated vs. detyrosinated or acetylated microtubules using immunofluorescence with specific antibodies .

  • Researchers should measure fluorescence intensity ratios of these modifications to assess shifts in microtubule stability populations.

  • Western blot quantification of these modifications provides complementary biochemical confirmation of immunofluorescence observations.

• Live-cell imaging parameters:

  • Transfection with fluorescently-tagged EB3 (e.g., EB3-GFP) to visualize microtubule plus-end dynamics as "comets" .

  • Quantitative metrics to measure include:

    • Comet density (number of growing microtubule ends per area)

    • Comet velocity (growth rate of microtubules)

    • Comet lifetime (persistence of growth before catastrophe)

    • Directionality of growth (particularly relevant in polarized cells like neurons)

• Neurite morphology measurements:

  • Axon length measurements following FIGN manipulation provide functional readouts of altered microtubule dynamics .

  • Branching analysis: Quantification of branch number, branch order, and branch length correlates with changes in the labile microtubule population .

  • Growth cone morphology and dynamics assessment can reveal altered microtubule behaviors at the leading edge.

• Fluorescence recovery after photobleaching (FRAP):

  • FRAP of fluorescently-labeled tubulin provides measures of microtubule turnover rates.

  • Key parameters include recovery half-time and mobile fraction, which reflect microtubule stability.

• Protein-protein interaction quantification:

  • Co-immunoprecipitation followed by Western blot to quantify FIGN-EB3 interactions under different conditions .

  • Proximity ligation assays can provide spatially resolved quantification of these interactions within specific cellular compartments.

By combining these quantitative approaches, researchers can comprehensively characterize how FIGN manipulation affects both the static state and dynamic behavior of the microtubule cytoskeleton, providing deeper insights into the mechanisms underlying FIGN's role in axonal growth and regeneration.

What optimization steps are critical for successful Western blot detection of FIGN?

Optimizing Western blot protocols for FIGN detection requires attention to several critical parameters to achieve specific and robust signals:

• Sample preparation considerations:

  • Lysis buffer selection: Use buffers that effectively solubilize membrane and nuclear proteins, as FIGN can localize to both cytoplasm and nucleus .

  • Protease inhibitors: Include a complete protease inhibitor cocktail to prevent degradation of the full-length 82 kDa FIGN protein .

  • Sample denaturation: Heat samples at 95°C for 5 minutes in reducing sample buffer to ensure complete denaturation.

• Gel electrophoresis parameters:

  • Gel percentage: Use 8% or 10% SDS-PAGE gels to achieve optimal resolution around the 82 kDa range where FIGN migrates .

  • Loading control selection: GAPDH (37 kDa) provides good separation from FIGN and has been successfully used in previous studies .

• Antibody optimization:

  • Concentration titration: Start with 3 μg/mL for anti-FIGN antibodies based on successful previous applications .

  • Incubation conditions: Primary antibody incubation overnight at 4°C often yields better results than shorter incubations at room temperature.

  • Secondary antibody selection: HRP-conjugated anti-rabbit secondary antibodies at 1:2000 dilution have proven effective for rabbit polyclonal FIGN antibodies .

• Detection system considerations:

  • Enhanced chemiluminescence (ECL) provides sufficient sensitivity for FIGN detection in most cell and tissue lysates.

  • Exposure time optimization: Start with short exposures (30 seconds) and increase as needed to avoid oversaturation.

• Verification approaches:

  • Positive controls: Include lysates from cells known to express FIGN, such as HeLa or HEK-293T cell lines .

  • Recombinant protein: Where available, include recombinant human FIGN protein as a reference standard .

  • Molecular weight verification: The predicted band size for human FIGN is 82 kDa; verify that your detected band aligns with this size .

By systematically optimizing these parameters, researchers can develop robust Western blot protocols for specific and reproducible detection of FIGN protein in their experimental systems.

How can researchers effectively use FIGN antibodies in immunohistochemistry and immunofluorescence applications?

Effective use of FIGN antibodies in immunohistochemistry (IHC) and immunofluorescence (IF) applications requires careful consideration of tissue preparation, antibody selection, and detection protocols:

• Tissue preparation protocols:

  • For IHC: Formalin-fixed, paraffin-embedded (FFPE) tissues have been successfully used with FIGN antibodies .

  • For IF on cultured cells: 4% paraformaldehyde fixation for 15-20 minutes at room temperature preserves both FIGN and microtubule structures.

  • Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is recommended for FFPE tissues to unmask epitopes .

  • Permeabilization: 0.1-0.3% Triton X-100 in PBS for 5-10 minutes is suitable for accessing intracellular FIGN in IF applications.

• Antibody application parameters:

  • Concentration: For IHC, 20 μg/ml of FIGN antibody has been successfully used with DAB staining .

  • Incubation conditions: Overnight incubation at 4°C typically yields optimal results with minimal background.

  • Blocking: Use 5-10% normal serum (from the same species as the secondary antibody) with 1% BSA to reduce non-specific binding.

• Detection systems:

  • For IHC: DAB (3,3'-diaminobenzidine) staining provides stable and permanent visualization of FIGN .

  • For IF: Secondary antibodies conjugated to fluorophores compatible with available microscopy systems (e.g., Alexa Fluor dyes).

  • Signal amplification: Consider using biotin-streptavidin systems for weak signals, particularly in tissues with low FIGN expression.

• Co-staining strategies for IF:

  • FIGN + microtubule markers: Co-staining with antibodies against α-tubulin or specific post-translational modifications (e.g., tyrosinated tubulin) can reveal relationships between FIGN and its substrate .

  • FIGN + EB3: Co-localization analysis of FIGN with EB3 provides insights into their functional interaction at microtubule ends .

  • Axonal markers: In neuronal studies, combining FIGN staining with axonal markers helps visualize effects on axon growth and branching .

• Controls and validation:

  • Positive control tissues: Include liver and kidney sections, which have been documented to express detectable levels of FIGN .

  • Negative controls: Omit primary antibody or use tissues from FIGN knockout models when available.

  • Peptide competition: Pre-incubation of the antibody with immunizing peptide should abolish specific staining.

By following these guidelines, researchers can effectively visualize FIGN distribution and localization in tissues and cells, enabling studies of its expression patterns and relationship to microtubule structures and other interacting proteins.

How can FIGN antibodies be utilized to investigate the therapeutic potential of FIGN modulation in neurological disorders?

FIGN antibodies serve as essential tools for investigating FIGN's therapeutic potential in neurological disorders, particularly those involving axonal injury or degeneration:

• Preclinical model development and validation:

  • FIGN antibodies can be used to verify knockdown efficiency following AAV9-U6-shFign-GFP delivery in spinal cord injury models .

  • Immunohistochemical analysis using these antibodies can confirm spatial and temporal patterns of FIGN expression in relevant neuronal populations before and after injury.

  • Quantitative Western blot analysis with FIGN antibodies provides biochemical confirmation of intervention effectiveness in animal models.

• Mechanism-of-action studies:

  • Co-immunostaining with FIGN antibodies and markers for tyrosinated microtubules allows visualization of the relationship between FIGN depletion and increased labile microtubule populations .

  • Combining FIGN antibodies with EB3 staining helps elucidate the mechanistic pathway by which FIGN regulates microtubule dynamics through interaction with end-binding proteins .

  • These mechanistic insights are critical for understanding the therapeutic effects of FIGN modulation.

• Therapeutic target identification:

  • FIGN antibodies can identify specific domains or regions of the protein that interact with EB3 or other binding partners .

  • This structural information can guide the design of small molecule inhibitors or peptide-based therapeutics that disrupt specific FIGN functions while preserving others.

• Biomarker development:

  • In patient samples or experimental models, FIGN antibodies can assess whether FIGN expression levels correlate with disease severity or regenerative capacity.

  • Such correlations might identify patient subpopulations most likely to benefit from FIGN-targeting therapies.

• Combination therapy approaches:

  • FIGN antibodies can help evaluate whether FIGN modulation synergizes with other regenerative approaches, such as growth factor treatment or rehabilitation.

  • Immunohistochemical analysis can reveal whether such combinations enhance effects on axonal growth or branching beyond what is achieved with single interventions.

• Translational research applications:

  • For potential clinical translation, FIGN antibodies can verify target engagement of therapeutic candidates designed to modulate FIGN function.

  • They can also help establish pharmacodynamic markers by monitoring downstream effects on microtubule stability.

The existing evidence that FIGN depletion promotes axon regeneration after DRG injury and spinal cord injury highlights the significant therapeutic potential of this approach . FIGN antibodies are indispensable tools for advancing this research toward clinical applications for traumatic injuries, neurodegenerative disorders, and other conditions involving compromised axonal integrity.

What emerging technologies could enhance the specificity and sensitivity of FIGN detection in complex biological samples?

Several emerging technologies hold promise for enhancing the specificity and sensitivity of FIGN detection in complex biological samples:

• Advanced immunological approaches:

  • Single-domain antibodies (nanobodies): These smaller antibody fragments can access epitopes that might be sterically hindered for conventional antibodies, potentially improving FIGN detection in spatial contexts where the protein is part of complex structures .

  • LSTM-based antibody engineering: Machine learning approaches using Long Short-Term Memory networks can generate higher-affinity antibodies with improved specificity for FIGN. Research has demonstrated that such approaches can yield antibodies with over 1800-fold higher affinity than parental clones .

• Proximity-based detection methods:

  • Proximity Ligation Assay (PLA): This technique could significantly enhance detection of FIGN interactions with binding partners like EB3, providing spatial resolution of these interactions within cells .

  • BioID or APEX2 proximity labeling: Fusing FIGN with biotin ligases would allow identification of proximal proteins in living cells, providing insights into its dynamic interaction network in different cellular states.

• Advanced imaging technologies:

  • Super-resolution microscopy: Techniques such as STORM, PALM, or STED microscopy could reveal the precise localization of FIGN at microtubule severing sites with nanometer resolution, overcoming the diffraction limit of conventional microscopy.

  • Expansion microscopy: Physical expansion of samples could separate densely packed structures, allowing better visualization of FIGN's association with microtubule networks.

• Single-cell analysis approaches:

  • Single-cell proteomics: Emerging mass spectrometry approaches for single-cell analysis could detect FIGN expression variations across individual cells in heterogeneous populations.

  • Spatial transcriptomics combined with protein detection: Methods like Visium or MERFISH could correlate FIGN protein localization with transcriptional profiles in tissue contexts.

• Multiplexed detection systems:

  • Mass cytometry (CyTOF): Metal-conjugated antibodies against FIGN and other cytoskeletal proteins could enable highly multiplexed analysis of dozens of proteins simultaneously in single cells.

  • Cyclic immunofluorescence: Sequential staining and bleaching cycles could allow visualization of FIGN alongside numerous other markers in the same sample, providing rich contextual information.

• Computational and AI-assisted analysis:

  • Deep learning image analysis: Neural networks trained on FIGN staining patterns could enhance detection of subtle phenotypes following experimental manipulations.

  • Integrative multi-omics approaches: Combining FIGN protein data with transcriptomics and other datasets could provide systems-level insights into its functional roles.

These emerging technologies promise to overcome current limitations in detecting and functionally characterizing FIGN in complex biological contexts, potentially accelerating both basic research and therapeutic applications targeting this important microtubule regulator.

How do researchers integrate FIGN antibody-based studies with emerging computational approaches to study cytoskeletal dynamics?

Integration of FIGN antibody-based experimental data with computational approaches creates powerful synergies for understanding cytoskeletal dynamics:

This integration of experimental and computational approaches represents a frontier in cytoskeletal research, with the potential to accelerate both mechanistic understanding and therapeutic development targeting FIGN and related proteins.